6 results
Tuberculosis Overview

10 million new M. tuberculosis infections/year
Facultative intracellular rod-shaped bacteria
Multidrug-resistant tuberculosis (MDR-TB) accounts for 4.6% of
) Pathophysiology ... (Anorexia) • Night ... Treatment: Active ... Initiating Treatment ... #Management #Treatment
Tuberculosis Overview

10 million new M. tuberculosis infections/year
Facultative intracellular rod-shaped bacteria
Multidrug-resistant tuberculosis (MDR-TB) accounts for 4.6% of
) Pathophysiology ... (Anorexia) • Night ... Treatment: Active ... Initiating Treatment ... #Management #Treatment
IDSA - Clinical Strategy to Build an Individualized Treatment Regimen for Multi-Drug Resistant Tuberculosis (MDR-TB)
 •
Individualized Treatment ... Multi-Drug Resistant Tuberculosis ... 1: Choose one later-generation ... #MDRTB #management ... #regimens #pharmacology
Lung Abscess - Diagnosis and Management Summary

Lung Abscess Etiology:
 • Necrosis of lung parenchyma by a
Diagnosis and Management ... Lung Abscess Pathophysiology ... degrees • Chills, night ... CXR upright or lat ... westermani • Other: TB
IDSA Recommendations for Treating Mycobacterium Tuberculosis Infection and Disease in HIV-AIDS
Treating LTBI (to prevent TB disease)
Indications:
Mycobacterium Tuberculosis ... for active or latent ... #Treatment #management ... opportunistic #infections #HIVAIDS ... #pharmacology
IDSA Recommendations for Treating Treponema pallidum Infections (Syphilis) to Prevent Disease in HIV-AIDS
Early Stage (Primary, Secondary,
1 dose (BII) Late-Latent ... 28 days (BIII) Late-Stage ... IDSA #Prevention #Treatment ... #infections #HIVAIDS ... #pharmacology